Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery
Claes Held(Uppsala University), Lars Wallentin(Boehringer Ingelheim (United States)), Marc J. Claeys(Antwerp University Hospital), Jay Horrow(Wilmington University), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Robert F. Storey(University of Sheffield), Steen Husted(Aarhus University Hospital), J. Ycas(AstraZeneca (United States)), Benjamin M. Scirica(Brigham and Women's Hospital), Robert A. Harrington(Clinical Research Institute), Nils Åsenblad(Uppsala University), Stefan James(Uppsala University Hospital), Jean Pierre Bassand(Observatoire des Sciences de l’Univers Terre Homme Environnement Temps Astronomie), Christopher P. Cannon(Brigham and Women's Hospital), José Carlos Nicolau(Copenhagen University Hospital), M. Vintila(Carol Davila University of Medicine and Pharmacy), Richard C. Becker(Sabin Vaccine Institute)
Cited by 538
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k